drugset / Trial / NCT00646880

A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring

NCT00646880

Phase 3 Completed 41 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to compare the difference between tolterodine prolonged release (PR) and propiverine in efficacy as assessed by the AUM and to show that tolterodine PR is similar to propiverine with respect to micturition chart variables and safety profile.

Timeline

Start
2003-03
Primary completion
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Propiverine Small molecule 20 mg
Comparator Tolterodine Small molecule 4 mg

Indications